The Genetic Basis of Cancer:
Molecular Mechanisms, Hallmarks, and Bioethical Implications
ETHC 210: Ethics in Biotechnology / Bioethics — Quiz 6
Liberty University
Department of Biology & Health Sciences
June 10, 2026
Abstract
Cancer is fundamentally a genetic disease driven by the accumulation of mutations in two
classes of genes: proto-oncogenes and tumor suppressor genes. This paper provides a
comprehensive review of the molecular genetics underlying cancer, including the
gain-of-function mutations that convert proto-oncogenes into oncogenes, the
loss-of-function mutations that disable tumor suppressors such as p53 and BRCA1/2, and
Knudson's Two-Hit Hypothesis distinguishing hereditary from sporadic cancer. The
biological hallmarks of cancer—evasion of apoptosis, sustained angiogenesis, and
metastasis—are examined as consequences of these genetic alterations. The paper further
addresses the bioethical dimensions of predictive genetic testing, including the protections
and limitations of the Genetic Information Nondiscrimination Act (GINA), the ethical
obligations surrounding hereditary mutation disclosure, and the moral evaluation of
germline gene editing technologies such as CRISPR/Cas9, with particular attention to
Christian worldview perspectives on stewardship, the sanctity of life, and the imago Dei.
Keywords: oncogenes, tumor suppressor genes, p53, BRCA1/2, angiogenesis, metastasis, GINA, bioethics,
CRISPR, Christian bioethics
, ETHC 210 — Genetic Basis of Cancer
1. The Molecular Genetics of Cancer
Cancer arises from the progressive accumulation of genetic mutations that disrupt the normal
regulatory mechanisms governing cell growth, division, and death. Two principal categories of
genes are implicated in carcinogenesis: proto-oncogenes and tumor suppressor genes.
Proto-oncogenes are normal genes that encode proteins promoting cell proliferation and growth;
when they undergo gain-of-function mutations, gene amplification, or chromosomal translocation,
they become oncogenes that drive uncontrolled cell division. The analogy of a gas pedal stuck to
the floor is apt: the signal for growth is continuously engaged regardless of the body's actual needs
(Vogelstein & Kinzler, 2015).
Tumor suppressor genes perform the complementary function of inhibiting cell cycle
progression, repairing DNA damage, or initiating programmed cell death (apoptosis). When these
genes undergo loss-of-function mutations, the "brakes" on cell division are removed. The p53 gene,
often called the "guardian of the genome," is the most critical tumor suppressor: it detects DNA
damage, halts the cell cycle to allow repair, and triggers apoptosis if the damage is irreparable.
Mutated in over 50% of all human cancers, p53 loss represents one of the most common events in
oncogenesis (Levine & Oren, 2009).
1.1 Knudson's Two-Hit Hypothesis and Hereditary Cancer
Knudson's Two-Hit Hypothesis provides the foundational model for understanding the
difference between sporadic and hereditary cancer. The hypothesis states that both alleles of a
tumor suppressor gene must be inactivated ("two hits") for cancer to develop. In sporadic cancers,
both hits occur somatically in a single cell over the individual's lifetime, resulting in later disease
onset. In hereditary cancers, one mutated allele is inherited through the germline and is present in
every cell from birth, so only one additional somatic hit is required—leading to earlier onset, higher
penetrance, and frequently multiple primary tumors (Knudson, 1971).
The BRCA1 and BRCA2 genes exemplify this model. These tumor suppressor genes are
responsible for repairing double-strand DNA breaks through homologous recombination. Inherited
mutations in BRCA1/2 drastically increase lifetime risk for hereditary breast and ovarian cancer,
with carriers facing risks of 55–72% for breast cancer and 39–44% for ovarian cancer by age 70
(Kuchenbauer et al., 2020). The hereditary nature of these mutations also raises significant ethical
questions about predictive testing, family disclosure, and prophylactic intervention.
1.2 Telomerase and Cellular Immortality
Normal somatic cells possess a finite replicative lifespan due to the progressive shortening of
telomeres—protective nucleotide caps at chromosome ends—with each cell division. When
telomeres reach a critical minimum length, the cell enters senescence or apoptosis. Cancer cells
circumvent this limitation by reactivating the enzyme telomerase, which rebuilds telomeres and
grants cells unlimited replicative potential—effectively "immortality." Telomerase activation is
observed in approximately 85–90% of human cancers and represents a key enabling characteristic
of malignant transformation (Shay & Bacchetti, 1997).
2. The Hallmarks of Cancer
Page 2
Molecular Mechanisms, Hallmarks, and Bioethical Implications
ETHC 210: Ethics in Biotechnology / Bioethics — Quiz 6
Liberty University
Department of Biology & Health Sciences
June 10, 2026
Abstract
Cancer is fundamentally a genetic disease driven by the accumulation of mutations in two
classes of genes: proto-oncogenes and tumor suppressor genes. This paper provides a
comprehensive review of the molecular genetics underlying cancer, including the
gain-of-function mutations that convert proto-oncogenes into oncogenes, the
loss-of-function mutations that disable tumor suppressors such as p53 and BRCA1/2, and
Knudson's Two-Hit Hypothesis distinguishing hereditary from sporadic cancer. The
biological hallmarks of cancer—evasion of apoptosis, sustained angiogenesis, and
metastasis—are examined as consequences of these genetic alterations. The paper further
addresses the bioethical dimensions of predictive genetic testing, including the protections
and limitations of the Genetic Information Nondiscrimination Act (GINA), the ethical
obligations surrounding hereditary mutation disclosure, and the moral evaluation of
germline gene editing technologies such as CRISPR/Cas9, with particular attention to
Christian worldview perspectives on stewardship, the sanctity of life, and the imago Dei.
Keywords: oncogenes, tumor suppressor genes, p53, BRCA1/2, angiogenesis, metastasis, GINA, bioethics,
CRISPR, Christian bioethics
, ETHC 210 — Genetic Basis of Cancer
1. The Molecular Genetics of Cancer
Cancer arises from the progressive accumulation of genetic mutations that disrupt the normal
regulatory mechanisms governing cell growth, division, and death. Two principal categories of
genes are implicated in carcinogenesis: proto-oncogenes and tumor suppressor genes.
Proto-oncogenes are normal genes that encode proteins promoting cell proliferation and growth;
when they undergo gain-of-function mutations, gene amplification, or chromosomal translocation,
they become oncogenes that drive uncontrolled cell division. The analogy of a gas pedal stuck to
the floor is apt: the signal for growth is continuously engaged regardless of the body's actual needs
(Vogelstein & Kinzler, 2015).
Tumor suppressor genes perform the complementary function of inhibiting cell cycle
progression, repairing DNA damage, or initiating programmed cell death (apoptosis). When these
genes undergo loss-of-function mutations, the "brakes" on cell division are removed. The p53 gene,
often called the "guardian of the genome," is the most critical tumor suppressor: it detects DNA
damage, halts the cell cycle to allow repair, and triggers apoptosis if the damage is irreparable.
Mutated in over 50% of all human cancers, p53 loss represents one of the most common events in
oncogenesis (Levine & Oren, 2009).
1.1 Knudson's Two-Hit Hypothesis and Hereditary Cancer
Knudson's Two-Hit Hypothesis provides the foundational model for understanding the
difference between sporadic and hereditary cancer. The hypothesis states that both alleles of a
tumor suppressor gene must be inactivated ("two hits") for cancer to develop. In sporadic cancers,
both hits occur somatically in a single cell over the individual's lifetime, resulting in later disease
onset. In hereditary cancers, one mutated allele is inherited through the germline and is present in
every cell from birth, so only one additional somatic hit is required—leading to earlier onset, higher
penetrance, and frequently multiple primary tumors (Knudson, 1971).
The BRCA1 and BRCA2 genes exemplify this model. These tumor suppressor genes are
responsible for repairing double-strand DNA breaks through homologous recombination. Inherited
mutations in BRCA1/2 drastically increase lifetime risk for hereditary breast and ovarian cancer,
with carriers facing risks of 55–72% for breast cancer and 39–44% for ovarian cancer by age 70
(Kuchenbauer et al., 2020). The hereditary nature of these mutations also raises significant ethical
questions about predictive testing, family disclosure, and prophylactic intervention.
1.2 Telomerase and Cellular Immortality
Normal somatic cells possess a finite replicative lifespan due to the progressive shortening of
telomeres—protective nucleotide caps at chromosome ends—with each cell division. When
telomeres reach a critical minimum length, the cell enters senescence or apoptosis. Cancer cells
circumvent this limitation by reactivating the enzyme telomerase, which rebuilds telomeres and
grants cells unlimited replicative potential—effectively "immortality." Telomerase activation is
observed in approximately 85–90% of human cancers and represents a key enabling characteristic
of malignant transformation (Shay & Bacchetti, 1997).
2. The Hallmarks of Cancer
Page 2
